Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Locoregionally Advanced Nasopharyngeal Carcinoma

Induction Chemotherapy Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy with or without Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: Meta-analysis of 1,096 Patients from 11 Randomized Controlled Trials

“…Patients were divided into two groups: concurrent radiochemotherapy (Group CCRT, n=49) and radiotherapy (Group RT, n=46). Significant differences were found in 5-year OS and metastasis-free rates in favor of Group CCRT (X 2 =3.96~8.26, P<0.05) (Yu et al, 2012). Zhang et al (Zhang et al, 2010) conducted a meta-analysis of CCRT versus RT alone in NPC treatment which included 7 RCTs (totally 1608 patients), 2,3 and 5 years OS were improved significantly in the CCRT alone group (Risk ratio 0.63, 95%CI 0.50-0.80, Risk ratio 0.76, 95%CI 0.61-0.93, and Risk ratio 0.74, 95%CI 0.62-0.89).…”

Comparison of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: a Meta-analysis of 793 Patients from 5 Randomized Controlled Trials

“…Patients were divided into two groups: concurrent radiochemotherapy (Group CCRT, n=49) and radiotherapy (Group RT, n=46). Significant differences were found in 5-year OS and metastasis-free rates in favor of Group CCRT (X 2 =3.96~8.26, P<0.05) (Yu et al, 2012). Thephamongkhol et al (2004) conducted a meta-analysis of CCRT versus RT alone in NPC treatment which included 101 RCTs, 3-year OS and 5-year OS were improved significantly in the CCRT alone group (Odds Ratio 0.57, 95%CI 0.46-0.72 and Odds Ratio 0.68, 95%CI 0.46-0.99).…”

Abstract 4007: The identification of a microRNA signature associated with risk of distant metastasis in nasopharyngeal carcinoma

“…However, this has not contributed to treatment decisions, which to date, have relied on TNM staging, with administration of combined CRT for patients with locally-advanced disease. However, such CRT regimens are also associated with significant acute and long-term morbidities and even mortality, diluting any potential gains with these aggressive treatments [12][13][14]. Hence, the utility of this 4-miRNA signature, which has been validated in an independent cohort (Figure 1) and demonstrated to add to the prognostic value of the TNM staging category (Figure 2), is extremely promising.…”